Antimicrobial makers may need Centre's nod before seeking licences
New Delhi, Nov. 20 -- The Union health ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, that would require manufacturers of antimicrobials to obtain central permission before they can apply to a state for a manufacturing licence.
The draft notification dated November 6 proposes to include antimicrobials in the definition of "new drug" under the rules, the ministry said in a statement on Thursday. Manufacturers would then need permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the state licensing authority (SLA) concerned. "This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products," the statement said.
Currently, state licensing authorities grant manufacturing licences for these products, and the amendment was prompted by concerns that some were cleared without adequate regulatory scrutiny, including studies such as bioavailability/bioequivalence and stability studies, according to people aware of the matter. "Substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety," the ministry said.
A senior health ministry official who asked not to be named said licences already granted will remain valid, and existing licence holders will not have to reapply. "The measure is part of the government's broader efforts to promote the responsible use of antimicrobials, safeguard patient safety and address the growing public health challenge of anti-microbial resistance (AMR)," the official said....
To read the full article or to get the complete feed from this publication, please
Contact Us.